Asymptomatic hyperglycemia in coronary heart disease: frequency and associated lipid and lipoprotein levels in the bezafibrate infarction prevention (BIP) register. The BIP Study Group.
The lipid profile of patients with type-II diabetes is characterized by low levels of high-density lipoprotein cholesterol, hypertriglyceridemia, and increased levels of lipoprotein (a), all of which may affect the prognosis in patients with atherosclerotic cardiovascular disease. This study aimed to assess the prevalence of asymptomatic hyperglycemia and the associated lipid profile in a large group of patients with documented coronary heart disease. From February 1990 to October 1992, 14,326 patients aged 45-74 years with documented coronary heart disease (a history of myocardial infarction or angina pectoris) were screened for inclusion in a secondary prevention study using bezafibrate retard. All screened patients underwent a medical examination and a blood test after fasting for 14 h. Asymptomatic hyperglycemia was defined as a fasting blood glucose level of 140 mg/dl or above in patients with no previous history of diabetes mellitus. The prevalence of asymptomatic hyperglycemia was 4%, with no differences between the sexes or age groups. Total cholesterol and triglyceride levels were significantly higher and the high-density lipoprotein cholesterol level significantly lower in asymptomatic hyperglycemic than in normoglycemic patients. After multiple adjustments, the relative risk of death was 1.75 and 1.71 in patients with diabetes or asymptomatic hyperglycemia compared with those with no glycemic disorders. Asymptomatic hyperglycemia was detected in 4% of patients with ischemic heart disease. The lipid profile in these 4% resembles that of patients with confirmed diabetes, and their morbidity and mortality may therefore be higher than that of normoglycemic patients. Repeated assessment of glucose levels in patients with coronary heart disease is mandatory.